Biglycan, also known as PG I, is a secreted chondroitin/dermatan sulfate proteoglycan in the small leucine-rich proteoglycan (SLRP) family. SLRP family members are characterized by N-terminal and C-terminal cysteine-rich regions that flank a central region containing 10 - 12 tandem leucine-rich repeats (LRRs). Biglycan function is important in the development and maintenance of many tissues (1, 2). The human Biglycan cDNA encodes a 368 amino acid (aa) precursor with a 19 aa signal sequence and a 18 aa propeptide that is cleaved by BMP-1 (3). Mature Biglycan contains N-linked glycosylation in addition to two glycosaminoglycan (GAG) chains (4). The 45 kDa core protein is approximately one third the molecular weight of the fully glycanated form and can assemble into noncovalently-associated dimers (5). Human Biglycan shares 97% aa sequence identity with bovine, mouse, and rat Biglycan and 57% aa sequence identity with human Decorin. Biglycan binds several matrix proteins, including fibrillar collagens, Matrilin-1, and beta IG-H3 (6 - 8). Its multiple LRRs, N-linked glycosylation, and GAG chains mediate distinct interactions that enable extensive crosslinking and stabilization of the collagen matrix (6 - 8). Mature Biglycan can be further cleaved by proteases, resulting in non-glycanated fragments (9). In osteoarthritis, MMP-13-induced breakdown of Biglycan likely interferes with collagen crosslinking and contributes to cartilage degradation (10). Biglycan also binds and modulates the activity of a variety of non-matrix proteins, including BMP-4, C1q, collectins, TGF-beta, TNF-alpha, and WISP-1 (11, 12). Biglycan functions as a proinflammatory mediator by binding TLR2 and TLR4 on macrophages and inducing TNF-alpha and MIP-2 production (13). Biglycan knockout mice have compromised inflammatory responses and are resistant to LPS-induced septic shock (13). Biglycan binds HDL/Apolipoprotein E complexes in atherosclerotic plaques and also binds SR-A, blocking the uptake and degradation of LDL (14, 15).
Human Biglycan Antibody (303203)
R&D Systems | Catalog # MAB2667
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Key Product Details
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Asp38-Lys368
Accession # P21810
Specificity
Clonality
Host
Isotype
Scientific Data Images for Human Biglycan Antibody (303203)
Detection of Human Biglycan by Western Blot
The expression levels of hub genes in GC. (A) The mRNA expression was correlated with pathological T stages. The asterisk represents the comparison between a specific stage and the normal group, or between different stages. * p < 0.05, ** p < 0.01, *** p < 0.001. (B) Representative western blotting for COL10A1, BGN, and FAP proteins in 4 paired gastric tumor (T) and adjacent non-tumor tissues (N) with progressive stages from T1 to T4. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35328635), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human Biglycan Antibody (303203)
Western Blot
Sample: Recombinant Human Biglycan (Catalog # 2667-CM)
Formulation, Preparation, and Storage
Purification
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Calculators
Background: Biglycan
References
- Hocking, A.M. et al. (1998) Matrix Biol. 17:1.
- Yoon, J.H. and J. Halper (2005) J. Musculoskelet. Neuronal Interact. 5:22.
- Scott, I.C. et al. (2000) J. Biol. Chem. 275:30504.
- Fisher, L.W. et al. (1989) J. Biol. Chem. 264:4571.
- Scott, P.G. et al. (2006) J. Biol. Chem. 281:13324.
- Schonherr, E. et al. (1995) J. Biol. Chem. 270:2776.
- Wiberg, C. et al. (2003) J. Biol. Chem. 278:37698.
- Reinboth, B. et al. (2006) J. Biol. Chem. 281:7816.
- Roughley, P.J. et al. (1996) Biochem. J. 318:779.
- Monfort, J. et al. (2006) Arthritis Res. Ther. 8:R26.
- Groeneveld, T.W.L. et al. (2005) J. Immunol. 175:4715.
- Moreno, M. et al. (2005) EMBO J. 24:1397.
- Schaefer, L. et al. (2005) J. Clin. Invest. 115:2223.
- Olin, K.L. et al. (2001) Arterioscler. Thromb. Vasc. Biol. 21:129.
- Santiago-Garcia, J. et al. (2003) J. Biol. Chem. 278:6942.
Alternate Names
Gene Symbol
UniProt
Additional Biglycan Products
Product Documents for Human Biglycan Antibody (303203)
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Note: Certificate of Analysis not available for kit components.
Product Specific Notices for Human Biglycan Antibody (303203)
For research use only
Related Research Areas
Citations for Human Biglycan Antibody (303203)
Customer Reviews for Human Biglycan Antibody (303203)
There are currently no reviews for this product. Be the first to review Human Biglycan Antibody (303203) and earn rewards!
Have you used Human Biglycan Antibody (303203)?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 for a review with an image
$10/€7/£6/$10CAN/¥1110 for a review without an image
Submit a review
Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
- Cellular Response to Hypoxia Protocols
- R&D Systems Quality Control Western Blot Protocol
- Troubleshooting Guide: Western Blot Figures
- Western Blot Conditions
- Western Blot Protocol
- Western Blot Protocol for Cell Lysates
- Western Blot Troubleshooting
- Western Blot Troubleshooting Guide
- View all Protocols, Troubleshooting, Illustrated assays and Webinars